摘要
目的:观察铜绿假单胞菌制剂经胸腔注入治疗恶性胸腔积液的临床疗效。方法:将84例恶性胸腔积液患者按入院先后顺序随机分组,治疗组43例给予铜绿假单胞菌制剂胸腔注入治疗,对照组41例给予顺铂胸腔注入治疗,对临床疗效及毒副作用进行比较观察。结果:治疗组有效率明显高于对照组(P<0.05)。在毒副作用方面,除了治疗组中7例(16.3%)出现轻度发热,9例(18.6%)出现轻度胸痛,其他方面毒副作用明显少于对照组(P<0.05)。结论:铜绿假单胞菌制剂经胸腔注入治疗恶性胸腔积液是一种安全有效的治疗手段。
Objective：To observe the clinical effect of PA-MSHA administration through intrapericardial infusion in the treatment of malignant pleural effusion. Methods：84 cases of malignant pleural effusion patients were randomly divided into treatment group （43 cases） and control group （41 cases）. In the treatment group,the patients received PA-MSHA administration through intrapericardial infusion; in the control group,the patients received Cisplatin through intrapericardial infusion. We evaluated the clinical effect,side effect and toxicity. Results：The response rate of the treatment group was higher than that of control group （P〈0.05）. The patients in the treatment group occurred lower side effects and toxicity than that of in the the control group （P〈0.05）,except that 7 cases（16.3%） occurred fever and 9 cases（18.6%） occurred chest pain. Conclusion：PA-MSHA administration through intrapericardial infusion in the treatment of malignant pleural effusion is an effective,safe therapeutic way.
出处
《中国医药导报》
CAS
2010年第10期103-104,共2页
China Medical Herald
